Carvedilol (CVL), a β-adrenergic receptor antagonist, promotes NF-κB nuclear translocation through the NLRP3-caspase-1-ASC inflammasome, inducing pyroptosis in prostate cancer (PCa) cells and establishing a foundation for the application of β-adrenergic antagonists in PCa treatment (165). Here, CASP1 is linked to prostate cancer.